Literature DB >> 26869417

Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.

Liem Andhyk Halim1, Vera Brinks1, Wim Jiskoot2, Stefan Romeijn2, Rob Haselberg3, Chris Burns4, Meenu Wadhwa4, Huub Schellekens5.   

Abstract

Comprehensive physicochemical characterization and biological assays are essential parts in assessing quality attributes of biologicals. Here, we compared the quality of different marketed recombinant human erythropoietin (epoetin) products: originators, Eprex and NeoRecormon as well as 2 biosimilars, Retacrit and Binocrit. In addition, assessment of batch-to-batch variability was included by collecting 2 or more batches of each product. Common assays which included sodium dodecyl sulfate-polyacrylamide gel electrophoresis, high-performance size-exclusion chromatography, asymmetrical flow field-flow fractionation, capillary zone electrophoresis, and potency testing were used. Of the tested products and among batches of single products, variations in epoetin content, isoform profiles, and potency were found. Ultimately, this study demonstrated the high quality of epoetin products with some degree of variation among products and batches, confirming the "similar but not identical" paradigm of biologicals.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  biosimilar; immunogenicity; physicochemical properties; protein characterization; recombinant human erythropoietin

Mesh:

Substances:

Year:  2016        PMID: 26869417     DOI: 10.1016/j.xphs.2015.10.019

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

1.  Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.

Authors:  Roberto Minutolo; Piergiorgio Bolasco; Paolo Chiodini; Stefano Sposini; Maurizio Borzumati; Cataldo Abaterusso; Alessandra A Mele; Domenico Santoro; Valeria Canale; Alberto Santoboni; Oliviero Filiberti; Fulvio Fiorini; Carlo Mura; Patrizio Imperiali; Silvio Borrelli; Luigi Russo; Luca De Nicola; Domenico Russo
Journal:  Clin Drug Investig       Date:  2017-10       Impact factor: 2.859

2.  Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plans.

Authors:  Leroy R A Lepelaars; Francesca Renda; Luca Pani; Giuseppe Pimpinella; Hubert G M Leufkens; Gianluca Trifirò; Giovanni Tafuri; Aukje K Mantel-Teeuwisse; Francesco Trotta
Journal:  Br J Clin Pharmacol       Date:  2018-01-18       Impact factor: 4.335

3.  Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?

Authors:  David Goldsmith; Frank Dellanna; Martin Schiestl; Andriy Krendyukov; Christian Combe
Journal:  Clin Drug Investig       Date:  2018-06       Impact factor: 2.859

4.  Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars.

Authors:  Hans C Ebbers; Bjørn Fehrmann; Mette Ottosen; Niels Hvorslev; Pia Høier; Jae-Woong Hwang; Jinhan Chung; Hyoung Taek Lim; Shinjung Lee; Juyoung Hong; Mourad Farouk Rezk
Journal:  BioDrugs       Date:  2020-04       Impact factor: 5.807

Review 5.  Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.

Authors:  Matti Aapro; Andriy Krendyukov; Martin Schiestl; Pere Gascón
Journal:  BioDrugs       Date:  2018-04       Impact factor: 5.807

Review 6.  The biosimilar pathway in the USA: An analysis of the innovator company and biosimilar company perspectives and beyond.

Authors:  Lin-Chau Chang
Journal:  J Food Drug Anal       Date:  2019-04-30       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.